It was indeed a remarkable moment in the history of diabetes management when Awiqli (insulin icodec) was launched in India by Novo Nordisk as the first-ever once-weekly basal insulin in the treatment of adults with either Type 1 or Type 2 diabetes. It may help cut down the frequency of injections of patients with insulin-dependent diabetes from 365 per year to 52, and therefore be one of the greatest advances in insulin-based treatments in decades.
Insulin treatment means a lot for millions of diabetic patients because it entails much more than mere consumption of an important drug for them—there is a painful and exhausting routine that one must observe every day. Failure to inject insulin regularly, postponement of treatment or skipping the treatment process because of the hassle associated with daily injections has always been a problem in the medical practice.
Being called the "diabetes capital of the world," India confronts a huge problem in the healthcare sector. The number of patients with diabetes in the country exceeds 101 million, and 136 million individuals suffer from prediabetes. Despite the availability of efficacious treatment options, the initiation of insulin treatment is usually delayed due to fear of injections, expected pain, and treatment costs. The launch of Awiqli may contribute to increasing the level of patient adherence to therapy and the use of insulin at the earliest possible time.
The key component of Awiqli is insulin icodec, which is a very long-acting basal insulin analogue designed to provide the stability of blood glucose levels during the whole week after a single dose. In contrast to standard basal insulins requiring administration on a daily basis, insulin icodec is active for about 7 days and keeps insulin concentration in the blood stable. Clinical trials have proved the ability of insulin icodec to provide adequate glycaemic control similar to that provided by daily basal insulin treatment.
The new development will have a significant effect on the quality of lives of the patients. Reduced frequency of injections will lead to reduced treatment fatigue, more convenience and increased adherence to the prescribed insulin regime. Increased adherence to the insulin regimes leads to good glucose management and reduces the risk of developing any other complications associated with diabetes including heart diseases, kidney damage, nerve injury and visual impairment. Despite the fact that Awiqli is not the cure of diabetes, it is considered to be a significant advancement in addressing the major barrier associated with insulin treatment.
It should be noted that the product has been introduced by Novo Nordisk in a competitive way in the Indian market. As per the company, the product will come in two prefilled pen versions and will be priced competitively to existing daily basal insulin treatments. It is expected that the product will be accessible for the patients from India soon after its introduction.
The fact that there is now a once-weekly insulin will provide more choices for doctors in providing treatment for patients with diabetes. It is, however, worth noting that according to health experts, Awiqli is a prescription drug and therefore it should only be started and monitored by licensed health practitioners. It is important to ensure that blood glucose tests are regularly performed and that medical professionals provide directions concerning dosage and lifestyle issues.
The launch of Awiqli is part of a new trend of making patient-focused innovations in the management of chronic illnesses. With most drug manufacturers concentrating on making treatments convenient and effective, such drugs may come to revolutionize the standards of care.
For Indian people suffering from diabetes, the introduction of Awiqli will not only mean a new drug but also a chance of making things easier. While reducing the number of injections from 365 to 52 annually may appear as a mere number, it will mean a lot for people with diabetes in terms of adherence and quality of life.
Team Yuva Aaveg-
Adarsh Tiwari
🌟 Join Yuva Aaveg! 🌟
A vibrant community dedicated to empowering youth with the latest insights, discussions, and updates on topics that matter. Connect with like-minded individuals, share ideas, and stay inspired to make a difference.
📲 Join us on WhatsApp and Telegram for exclusive updates and engaging conversations!
No comments:
Post a Comment
Please give your feedback and help us to give you best possible content!!